• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Michaud Charles Jr sold $1,815 worth of shares (75 units at $24.20), decreasing direct ownership by 7% to 927 units (SEC Form 4)

    4/23/24 5:00:03 PM ET
    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FIXX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Michaud Charles Jr

    (Last) (First) (Middle)
    Q32 BIO INC.
    830 WINTER STREET

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Q32 Bio Inc. [ QTTB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    03/25/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/25/2024 S(1) 75(2) D $24.2 927(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of the RSUs.
    2. On March 25, 2024, the Issuer effected a 1-for-18 reverse stock split (the "Reverse Stock Split"). The share counts herein have been adjusted to reflect the Reverse Stock Split.
    Remarks:
    Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc.
    /s/ Charles Michaud, Jr. 04/23/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FIXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FIXX

    DatePrice TargetRatingAnalyst
    7/28/2023$9.00 → $1.50Outperform → Neutral
    Robert W. Baird
    2/28/2022$30.00 → $20.00Buy
    HC Wainwright & Co.
    2/22/2022$25.00 → $9.00Buy
    B of A Securities
    2/22/2022$35.00 → $29.00Neutral
    BTIG Research
    2/22/2022Outperform → Sector Perform
    RBC Capital Mkts
    2/22/2022$25.00 → $15.00Buy
    Chardan Capital
    2/22/2022$35.00 → $29.00Buy
    BTIG
    2/22/2022$30.00 → $4.00Outperform → Sector Perform
    RBC Capital
    More analyst ratings

    $FIXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Homology Medicines downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously

      7/28/23 7:17:02 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Homology Medicines with a new price target

      HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously

      2/28/22 7:12:58 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B of A Securities reiterated coverage on Homology Medicines with a new price target

      B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously

      2/22/22 10:12:45 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Homology Medicines Inc.

      424B3 - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:26:07 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Homology Medicines Inc.

      10-Q - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:18:33 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:06:23 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

      BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients

      3/2/23 7:30:54 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines to Participate at Upcoming Conferences

      BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT

      10/6/22 8:30:27 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

      SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

      9/27/22 8:15:00 AM ET
      $AKUS
      $CINC
      $FIXX
      $IONS
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Homology Medicines Inc. (Amendment)

      SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

      5/13/24 5:34:55 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/4/24 8:33:33 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/1/24 9:52:41 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Leadership Updates

    Live Leadership Updates

    See more
    • Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

      - ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr

      8/5/21 8:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alloway Paul sold $6,488 worth of shares (268 units at $24.21), decreasing direct ownership by 9% to 2,596 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:03:07 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Michaud Charles Jr sold $1,815 worth of shares (75 units at $24.20), decreasing direct ownership by 7% to 927 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:00:03 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tzianabos Arthur

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      3/27/24 5:43:06 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Financials

    Live finance-specific insights

    See more
    • Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner

      Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business  Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t

      1/28/22 2:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care